Cell-specific activation of gemcitabine by endogenous H2S stimulation and tracking through simultaneous fluorescence turn-on.
Chem Commun (Camb)
; 57(75): 9614-9617, 2021 Sep 21.
Article
em En
| MEDLINE
| ID: mdl-34486009
ABSTRACT
The endogenous H2S-driven theranostic H2S-Gem has been invented. The theranostic prodrug H2S-Gem is selectively activated in cancer cells, releasing active gemcitabine with a simultaneous fluorescence turn-on. H2S-Gem selectively inhibited cancer cell growth compared to the mother chemotherapeutic gemcitabine. Overall, it is a unique protocol for tracking and transporting chemotherapeutic agents to tumor areas without the guidance of tumor-directive ligands.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pró-Fármacos
/
Desoxicitidina
/
Sulfeto de Hidrogênio
/
Antimetabólitos Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Chem Commun (Camb)
Ano de publicação:
2021
Tipo de documento:
Article